Drugs /

verteporfin

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and, once stimulated by nonthermal red light in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to neovascular endothelium and blood vessel occlusion. (NCI04)

Clinical Trials

View Clinical Trials for verteporfin

Verteporfin has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating verteporfin, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

EGFR Amplification and EGFR Mutation are the most frequent biomarker inclusion criteria for verteporfin clinical trials.

Glioblastoma and prostate carcinoma are the most common diseases being investigated in verteporfin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Verteporfin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating verteporfin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
benzoporphyrin derivative monoacid ring a, benzoporphyrin derivative monoacid ring a, verteporfin, verteporfinum, verteporfin (substance), verteporfin [chemical/ingredient], 129497-78-5, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23h,25h-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester, verteporfin (product), visudyne, verteporphin, bpd verteporfin, bpd-ma, verteporfina, verteporfin, vertéporfine
NCIT ID [1]:
C1014
SNOMED ID [1]:
F-61C16

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.